- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur.
The study is looking at:
- What side effects the study drug might cause
- How well the study drug works
- How much of the study drug is in the blood at different times
- If the body reacts to the study drug, in a way that may cause the study drug to not work as well
- What is the best dose of the study drug for treating previously treated, advanced solid tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Study Locations
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Carolina BioOncology Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroesophageal junction cancer, uveal melanoma, papillary renal cell carcinoma, or clear cell renal cell carcinoma) that is at an advanced stage as described in the protocol
- Participants must not be candidates for curative surgery or radiation
- Participants are required to have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy as described in the protocol
- Willing to provide tumor tissue; archival or fresh tumor tissue will be accepted as described in the protocol
- At least 1 lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ and bone marrow function as described in the protocol
Key Exclusion Criteria:
- Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device as described in the protocol
- Has received radiation therapy within the 28 days prior to first administration of study intervention. Palliative stereotactic radiation therapy without a thoracic or abdominal field is allowed with a washout period of 14 days from first administration of study intervention.
- Has undergone major surgery within the 14 days prior to first administration of study intervention
- Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy as described in the protocol
- Has a history of interstitial lung disease (eg, idiopathic pulmonary fibrosis, etc) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management or has imaging consistent with these diseases during the screening period. A history of radiation pneumonitis is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
- Has received prior treatment with an antibody-drug conjugate (ADC) that includes a topoisomerase payload
- Known active or untreated brain metastases or spinal cord compression. Participants are eligible if central nervous system (CNS) metastases are adequately treated, and participants have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment.
Note: Other protocol defined inclusion/ exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1: Dose Escalation
|
Administered per the protocol |
|
Experimental: Part 2: Dose Expansion
|
Administered per the protocol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of dose-limiting toxicities (DLTs)
Time Frame: Up to 21 days
|
Part 1 (Dose Escalation) |
Up to 21 days
|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of Serious Adverse Events (SAEs)
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Occurrence of adverse event of special interests (AESIs)
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response (investigator assessed) per RECIST 1.1
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) |
Up to approximately 5 years
|
|
Concentrations of ADC
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of total antibody
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Concentrations of payload (ProDXd and DXd)
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of Anti-Drug Antibodies (ADA) against REGN13089-M404-M2980
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Magnitude of ADA against REGN13089-M404-M2980
Time Frame: Up to approximately 5 years
|
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Duration of response per RECIST 1.1
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Time to response per RECIST 1.1
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Progression-free survival per RECIST 1.1
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Overall survival
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Occurrence of TEAEs considered clinically significant
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
|
Laboratory abnormalities considered clinically significant
Time Frame: Up to approximately 5 years
|
Part 2 (Dose Expansion) |
Up to approximately 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- NSCLC
- MET
- Colorectal cancer
- Gastric cancer
- Non-small cell lung cancer
- Advanced cancer
- Metastatic
- Unresectable
- Gastroesophageal junction cancer
- Metastatic solid tumor
- ADC
- First-in-human
- Uveal melanoma
- Antibody-drug conjugate
- Clear cell renal cell carcinoma
- FIH
- Advanced solid malignancy
- Papillary renal cell carcinoma
- METxMET antibody-drug conjugate
- Solid neoplasm
- Unresectable solid tumor
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Lung Diseases
- Eye Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Neoplastic Processes
- Lung Neoplasms
- Urologic Neoplasms
- Carcinoma
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Kidney Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Eye Neoplasms
- Uveal Diseases
- Melanoma
- Pathological Conditions, Signs and Symptoms
- Uveal Neoplasms
- Stomach Neoplasms
- Colorectal Neoplasms
- Neoplasm Metastasis
- Carcinoma, Renal Cell
- Carcinoma, Non-Small-Cell Lung
- Uveal Melanoma
Other Study ID Numbers
- R13089-ONC-25128
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD Sharing Time Frame
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD Sharing Access Criteria
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.